GlassScriptPhysician profile
Lindsey Page
NPI 1265726152
$3,537.06
in general payments reported to CMS, 2019-2025
41 companies · $2,250 in 2025
The $2,250 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $228 · 2022: $42.38 · 2023: $17.66 · 2024: $999 · 2025: $2,250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,141 · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,140.72 |
| Education | $125.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $397.34 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $356.27 | 2021-2025 | |
| Astellas Pharma US INC | $338.33 | 2024-2025 | Xtandi, Vyloy, Padcev |
| Janssen Biotech, INC. | $293.38 | 2024-2025 | Tecvayli, Erleada, Rybrevant |
| Amgen INC. | $182.87 | 2021-2025 | Nplate, Vectibix, Vectibix |
| Abbvie INC. | $173.21 | 2024-2025 | |
| Incyte Corporation | $152.86 | 2022-2025 | Jakafi, Zynyz, Monjuvi |
| Daiichi Sankyo INC. | $136.15 | 2024-2025 | Enhertu, Injectafer, Datroway |
| Jazz Pharmaceuticals INC. | $132.84 | 2021-2025 | |
| Pfizer INC. | $119.44 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $116.23 | 2024-2025 | Tagrisso, Lynparza, Enhertu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.59 | 2025 | |
| Eisai INC. | $106.33 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $89.07 | 2024-2025 | Ultomiris |
| Genmab U.S., INC. | $83.97 | 2024-2025 | Epkinly, Tivdak |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $74.19 | 2024-2025 | Fruzaqla, Ninlaro |
| Genentech USA, INC. | $60.50 | 2024-2025 | Polivy, Venclexta, Tecentriq Hybreza |
| Celgene Corporation | $59.99 | 2024-2025 | Reblozyl |
| Blueprint Medicines Corporation | $54.14 | 2024-2025 | Ayvakit |
| E.R. Squibb & Sons, L.L.C. | $44.67 | 2022-2024 | Opdualag, Opdivo |
| Regeneron Healthcare Solutions, INC. | $38.68 | 2024-2025 | Libtayo |
| Iovance Biotherapeutics, INC. | $33.57 | 2025 | Amtagvi |
| Immunocore Limited | $31.60 | 2025 | Kimmtrak |
| Array Biopharma INC | $29.63 | 2024 | Xalkori, Lorbrena, Braftovi |
| Coherus Oncology, INC. | $29.62 | 2025 | Loqtorzi |
| Caris Mpi, INC. | $25.12 | 2025 | Mi Cancer Seek |
| Emd Serono, INC. | $24.24 | 2025 | |
| Taiho Oncology, INC. | $21.92 | 2025 | |
| Tersera Therapeutics LLC | $21.03 | 2025 | Zoladex |
| Glaxosmithkline, LLC. | $20.48 | 2025 | Ojjaara |
| Progenics Pharmaceuticals, INC. | $19.89 | 2024 | |
| Stemline Therapeutics INC. | $18.97 | 2025 | Orserdu |
| Karyopharm Therapeutics INC. | $18.79 | 2025 | Xpovio |
| Sumitomo Pharma America, INC. | $17.67 | 2025 | Orgovyx |
| Adc Therapeutics America, INC. | $17.19 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.43 | 2025 | |
| Genzyme Corporation | $15.24 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $15.06 | 2025 | Onivyde |
| Alnylam Pharmaceuticals INC. | $14.98 | 2024 | Givlaari |
| Lilly USA, LLC | $14.85 | 2025 | Jaypirca, Verzenio |
| Apellis Pharmaceuticals, INC. | $13.73 | 2024 | Empaveli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Page listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.